STOCK TITAN

Squadron funds disclose 9.5% Lipocine (LPCN) stake as passive holding

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Squadron Master Fund LP and affiliated parties reported a significant passive stake in Lipocine Inc. common stock. They beneficially own 530,000 shares of Lipocine’s common stock, representing 9.5% of the class, based on 5,551,931 shares outstanding as of November 5, 2025.

Squadron Capital Management, LLC, as investment adviser to private funds including Squadron Master Fund LP, and its partners Matthew Sesterhenn and William Blank may be deemed beneficial owners of these shares, with shared voting and dispositive power over 530,000 shares and no sole power. They expressly disclaim beneficial ownership of the securities, and state the position is held in the ordinary course of business and not to change or influence control of Lipocine.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Squadron Master Fund LP
Signature:/s/ Matthew Sesterhenn
Name/Title:Partner, Squadron Partners LLC, its General Partner
Date:02/17/2026
Squadron Capital Management LLC
Signature:/s/ Matthew Sesterhenn
Name/Title:Partner
Date:02/17/2026
Matthew Sesterhenn
Signature:/s/ Matthew Sesterhenn
Name/Title:Matthew Sesterhenn
Date:02/17/2026
William Blank
Signature:/s/ William Blank
Name/Title:William Blank
Date:02/17/2026

FAQ

What stake in Lipocine Inc. (LPCN) does Squadron report on this Schedule 13G/A?

Squadron Master Fund LP and affiliated parties report beneficial ownership of 530,000 shares of Lipocine Inc. common stock, equal to 9.5% of the class, based on 5,551,931 shares outstanding as of November 5, 2025.

Who are the reporting persons on the Lipocine (LPCN) Schedule 13G/A filing?

The reporting persons are Squadron Master Fund LP, Squadron Capital Management, LLC, and individuals Matthew Sesterhenn and William Blank. Squadron Capital Management advises the funds, and Sesterhenn and Blank are partners with investment and voting discretion.

Is Squadron’s 9.5% Lipocine (LPCN) position a passive investment?

Yes. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Lipocine, other than activities solely in connection with a nomination under Rule 14a-11.

How much voting power does Squadron have over Lipocine (LPCN) shares?

The reporting persons have shared voting power over 530,000 shares and no sole voting power. They also report shared dispositive power over 530,000 shares and no sole dispositive power, reflecting coordinated control over the reported position.

How was Squadron’s 9.5% ownership in Lipocine (LPCN) calculated?

The 9.5% figure is based on 5,551,931 Lipocine common shares outstanding as of November 5, 2025, as reported by Lipocine on its Form 10-Q filed November 6, 2025, with 530,000 shares attributed to each reporting person.

Do Squadron Capital Management and its partners claim full beneficial ownership of Lipocine (LPCN) shares?

No. While they may be deemed beneficial owners as adviser and partners with discretion, Squadron Capital Management, Matthew Sesterhenn, and William Blank expressly disclaim beneficial ownership of the Lipocine securities reported in the statement under Rule 13d-4.
Lipocine Inc

NASDAQ:LPCN

LPCN Rankings

LPCN Latest News

LPCN Latest SEC Filings

LPCN Stock Data

48.08M
5.55M
Biotechnology
Pharmaceutical Preparations
Link
United States
SALT LAKE CITY